Optimizing the management of patients with ovarian cancer
DOI:
https://doi.org/10.15587/2313-8416.2015.42084Keywords:
tissue kallikreins, ovarian cancer, prognosis of survival, postoperative chemotherapy, index of precisionAbstract
The proposed model for prediction of disease outcome on the basis of assessing the level of tissue kallikreins has a high predictive value and accuracy index, and can be used to develop a strategy for post-operative chemotherapy.
Aim. Increase the effectiveness of the combined treatment of patients with ovarian cancer by predicting and individualization of treatment strategies based on analysis of the content of kallikreins 5 (hK5) and 13 (hK13).
Materials and methods. All the patients underwent a comprehensive examination. Histological studies were conducted in the tissue removed during surgery. All patients studied a content of kallikrein 5 and 13 in cytosolic extract of tumor that removed during surgery.
Results. It can be stated that in the cytosolic extract of tissue of malignant ovarian tumors observed increase in the concentration of hK5 and a tendency to decrease in the concentration of hK13. The concentration of hK5 increases and concentration of hK13 decreases during decreasing the degree of differentiation and increasing the disease stage.
Conclusions. Prospects for further research in this area relate not only to exploring the use of kallikrein in the diagnosis of ovarian cancer and prognosis of the results of his treatment, but also developing new ways of chemotherapeutic effects on tumor growth.
References
1. Antoneeva, I. I., Petrov, S. B. (2008). Markery apoptoza i proliferacii opuholevyh kletok v dinamike progressirovanija raka jaichnika. Onkologija, 10 (2), 234–237.
2. Kartashov, S. M., Akulina, O. O., Skryn'ka, T. V. (2008). Epidemiologija ta diagnostyka raku jajechnykiv. Kiev, 25.
3. Muhamed, Saidi Suhael' Ben, Peresun'ko, O. P., Meshhyshen, I. F. (2004). Pro- ta antyoksydantni pokaznyky krovi zhinok z puhlynamy jajechnykiv. Bukov. med. visn., 8 (1), 121–124.
4. Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., Thun, M. J. (2004). Cancer Statistics, 2004. CA: A Cancer Journal for Clinicians, 54 (1), 8–29. doi: 10.3322/canjclin.54.1.8
5. Rosso, M. D., Fibbi, G., Pucci, M. et al. (2002). Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin. Exp. Metastasis, 19, 193–207.
6. Fedorenko, Z. P., Gulak, L. O., Goroh, Je. L. et. al. (2008). Bjuleten' nacional'nogo kancer-rejestru Ukrai'ny. Vydannja № 9. Kiev, 45–46.
7. Maksimov, S. Ja. (2002). Himioterapija vtoroj linii raka jaichnikov. Vozmozhnosti preparata taksol. Vopr. onkologii, 48 (1), 99–101.
8. Olijnyk, A. Je. (2006). Morfologichni osoblyvosti stromy seroznyh puhlyn jajechnykiv riznogo stupenja zrilosti. Kharkiv, 17.
9. Vynnyk, Ju. O., Neffa, M. Ju., Kazmyruk, O. V. et. al. (2004). Vykorystannja diagnostychnyh mozhlyvostej UZD ta MRT u kombinovanomu likuvanni hvoryh na rak jajechnykiv. Ukr. radiol. zhurn., XII (4), 367–370.
10. Kartashov, S. M., Skrickaja, T. V., Jakovleva, N. G. et. al. (2006). Informativnost' osnovnyh metodov diagnostiki raka jaichnikov. Medicina segodnja i zavtra, 2, 115–118.
11. Crijns, A. P. G., Duiker, E. W., de Jong, S., Willemse, P. H. B., van der Zee, A. G. J., de Vries, E. G. E. (2006). Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. International Journal of Gynecological Cancer, 16 (S1), 152–165. doi: 10.1111/j.1525-1438.2006.00503.x
12. Sharkova, V. E. (2004). Rakovyj antigen SA 125 – biologija i diagnosticheskaja znachimost'. Klin. laboratornaja diagnostika, 12, 3–7.
13. Emami, N., Diamandis, E. P. (2008). Utility of Kallikrein-Related Peptidases (KLKs) as Cancer Biomarkers. Clinical Chemistry, 54 (10), 1600–1607. doi: 10.1373/clinchem.2008.105189
14. Axtell, A. E., Lee, M. H., Bristow, R. E., Dowdy, S. C., Cliby, W. A., Raman, S. et. al. (2007). Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer. Journal of Clinical Oncology, 25 (4), 384–389. doi: 10.1200/jco.2006.07.7800
15. Nolen, B., Marrangoni, A., Velikokhatnaya, L., Prosser, D., Winans, M., Gorelik, E., Lokshin, A. (2009). A serum based analysis of ovarian epithelial tumorigenesis. Gynecologic Oncology, 112 (1), 47–54. doi: 10.1016/j.ygyno.2008.09.043
16. Howells, R. E. J., Dhar, K. K., Hoban, P. R., Jones, P. W., Fryer, A. A., Redman, C. W. E., Strange, R. C. (2004). Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer. International Journal of Gynecological Cancer, 14 (2), 242–250. doi: 10.1111/j.1048-891x.2004.014207.x
17. Milde-Langosch, K., Hagen, M., Bamberger, A.-M., Lining, T. (2003). Expression and Prognostic Value of the Cell-cycle Regulatory Proteins, Rb, p16MTS1, p21WAF1, p27KIP1, Cyclin E, and Cyclin D2, in Ovarian Cancer. International Journal of Gynecological Pathology, 22 (2), 168–174. doi: 10.1097/00004347-200304000-00009
18. Lope, V., Pollán, M., Pérez-Gómez, B., Aragonés, N., Vidal, E., Gómez-Barroso, D. et. al. (2008). Municipal distribution of ovarian cancer mortality in Spain. BMC Cancer, 8 (1), 258. doi: 10.1186/1471-2407-8-258
19. Visintin, I., Feng, Z., Longton, G., Ward, D. C., Alvero, A. B., Lai, Y. et. al. (2008). Diagnostic Markers for Early Detection of Ovarian Cancer. Clinical Cancer Research, 14 (4), 1065–1072. doi: 10.1158/1078-0432.ccr-07-1569
20. Axtell, A. E., Lee, M. H., Bristow, R. E., Dowdy, S. C., Cliby, W. A., Raman, S. et. al. (2007). Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer. Journal of Clinical Oncology, 25 (4), 384–389. doi: 10.1200/jco.2006.07.7800
21. Diamandis, E. P., Yousef, G. M. (2002). Human tissue kallikreins: A family of new cancer biomarkers. Clin. Chem., 48, 1198–1205.
22. Ness, R. B., Grisso, J. A., Cottreau, C., Klapper, J., Vergona, R., Wheeler, J. E. et. al. (2000). Factors Related to Inflammation of the Ovarian Epithelium and Risk of Ovarian Cancer. Epidemiology, 11 (2), 111–117. doi: 10.1097/00001648-200003000-00006
Downloads
Published
Issue
Section
License
Copyright (c) 2015 Александр Леонидович Ивченко
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
